More info:

• armod

  The product in question is a wakefulness-promoting agent containing armodafinil as the active pharmaceutical ingredient. It represents the R-enantiomer of modafinil, developed to address excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work sleep disorder. Unlike many CNS stimulants that work through dopamine and norepinephrine pathways, this compound appears to modulate multiple neurotransmitter systems including glutamate, GABA, orexin, and histamine with a unique wake-promoting mechanism that’s distinct from traditional psychostimulants.

• Artvigil: Enhanced Wakefulness and Cognitive Function for Sleep Disorders - Evidence-Based Review

  Artvigil is a pharmaceutical-grade formulation of armodafinil, the R-enantiomer of modafinil, specifically developed for managing excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work sleep disorder. Unlike traditional stimulants that operate through broad catecholamine release, armodafinil demonstrates a more selective mechanism with wake-promoting effects primarily mediated through dopamine reuptake inhibition in specific hypothalamic nuclei. The “artvigil” branded product has gained particular attention for its consistent pharmacokinetic profile and cost-effectiveness compared to some other armodafinil preparations.

• modafresh

  Product Description Let me walk you through what we’ve been working with clinically – this isn’t your standard pharmaceutical product monograph but rather the collective clinical experience with modafresh, a wakefulness-promoting agent that’s been quite interesting in practice. We’ve been using it primarily for shift work sleep disorder and residual fatigue in patients where traditional stimulants weren’t appropriate. The formulation contains modafinil as the active component, typically in 100mg or 200mg tablets, though we’ve occasionally used compounded versions for specific patient needs.

• modaheal

  Modaheal represents one of the more interesting developments in wakefulness-promoting agents we’ve seen in recent years. It’s essentially a high-purity modafinil formulation that’s gained significant traction among sleep specialists and neurologists for managing excessive daytime sleepiness. What makes it stand out isn’t just the active compound itself—we’ve had modafinil variants for decades—but the specific manufacturing process and excipient profile that seems to yield more consistent plasma concentrations than some earlier formulations.

• Modalert: Enhanced Wakefulness and Cognitive Function - Evidence-Based Review

  Modafinil, sold under the brand name Modalert among others, is a wakefulness-promoting agent that’s been fascinating clinicians since its approval. It’s not your typical stimulant—doesn’t work on dopamine pathways the way amphetamines do, which is why it’s got such a different side effect profile. I remember when we first started using it off-label for shift work sleep disorder back in the early 2000s, the nursing staff on night rotations saw dramatic improvements in alertness without the jittery crashes.

• modvigil

  Modvigil is a pharmaceutical-grade preparation of modafinil, a wakefulness-promoting agent classified as a eugeroic. It’s primarily indicated for excessive daytime sleepiness associated with narcolepsy, shift work sleep disorder, and obstructive sleep apnea/hypopnea syndrome. Unlike traditional stimulants that work through dopamine pathways, modafinil has a unique multimodal mechanism that’s fascinated our research team for years. Modvigil: Enhanced Wakefulness and Cognitive Support - Evidence-Based Review 1. Introduction: What is Modvigil? Its Role in Modern Medicine Modvigil contains modafinil as its active pharmaceutical ingredient, developed as a successor to older stimulant medications that carried significant abuse potential and cardiovascular risks.

• Provigil: Sustained Wakefulness and Cognitive Support for Sleep Disorders - Evidence-Based Review

  Provigil, known generically as modafinil, is a wakefulness-promoting agent structurally distinct from traditional stimulants like amphetamines. It’s classified as a Schedule IV controlled substance in many countries due to its potential for dependence, though its abuse liability is considered lower than older stimulants. Initially developed in France in the late 1970s, it gained FDA approval in 1998 for narcolepsy and has since seen expanded off-label use for shift work sleep disorder, obstructive sleep apnea, and cognitive enhancement.

• vilafinil

  Vilafinil represents one of the more interesting developments in the wake of modafinil’s patent expiration. It’s essentially a generic formulation containing the active enantiomer armodafinil, which provides a cleaner, more sustained wakefulness promotion compared to the racemic modafinil. What struck me early on was how this seemingly simple generic was creating dramatically different responses in my narcolepsy patients—some thrived while others reported unusual side effects that didn’t align with the established profile.

• waklert

  Waklert represents one of the more interesting developments in our armamentarium for managing excessive daytime sleepiness, particularly in shift work sleep disorder and narcolepsy. As a senior neurologist who’s prescribed this medication for nearly a decade across multiple clinical settings, I’ve developed a nuanced understanding of its benefits and limitations that goes beyond the official prescribing information. The active pharmaceutical ingredient in Waklert is armodafinil, which is the R-enantiomer of modafinil.